Transparency and reproducibility of observational cohort studies using large healthcare databases.

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 3, 2016, Pages 325-332

  Wang, S V ^a   Verpillat, P ^b   Rassen, J A ^c   Patrick, A ^c   Garry, E M ^d   Bartels, D B ^b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Aetion   (United States)

^d IL   (United States)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; COHORT ANALYSIS; COMMUNITY; DATA BASE; DECISION MAKING; HEALTH CARE; HUMAN; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; ACCESS TO INFORMATION; FACTUAL DATABASE; OBSERVATIONAL STUDY; REPRODUCIBILITY; STANDARDS;

ACCESS TO INFORMATION; COHORT STUDIES; DATABASES, FACTUAL; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; PHARMACOEPIDEMIOLOGY; REPRODUCIBILITY OF RESULTS;

EID: 84958956038     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.329     Document Type: Article

References (43)

1. Begley, C.G., Ellis, L.M. Drug development: raise standards for preclinical cancer research. Nature 483, 531-533 (2012).
2. Kaiser, J. The cancer test. Science 348, 1411-1413 (2015).
3. Nosek, B.A. et al. Scientific standards. Promoting an open research culture. Science 348, 1422-1425 (2015).
4. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). http://www.encepp.eu/(2014). Accessed 13 December 2014.
5. PCORI Methodology Committee. (eds. Hickam, D., Totten, A., Berg, A., Rader, K., Goodman, S., Newhouse, R.) The PCORI Methodology Report. 2013. http://www.pcori.org/assets/2013/11/PCORIMethodology Report.pdf. Accessed 13 December 2014.
6. Dreyer, N.A. et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am. J. Manag. Care 16, 467-471 (2010).
7. Curtis, L.H. et al. Design considerations, architecture, use of the Mini-Sentinel distributed data system. Pharmacoepidemiol. Drug Saf. 21 Suppl 1, 23-31 (2012).
8. Collins, F.S., Tabak, L.A. Policy: NIH plans to enhance reproducibility. Nature 505, 612-613 (2014).
9. Goodman, S.K., Krumholz, H.M. Open science: PCORI's efforts to make study results and data more widely available. http://www. pcori.org/blog/open-science-pcoris-efforts-make-study results-anddata-more-widely available (2015).
10. Laine, C. et al. Clinical trial registration-looking back and moving ahead. N. Engl. J. Med. 356, 2734-2736 (2007).
11. Lash, T.L., Vandenbroucke, J.P. Should preregistration of epidemiologic study protocols become compulsory? Reflections and a counterproposal. Epidemiology 23, 184-188 (2012).
12. Williams, R.J., Tse, T., Harlan, W.R., Zarin, D.A. Registration of observational studies: is it time? CMAJ 182, 1638-1642 (2010).
13. ICH. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/(2014). Accessed 13 December 2014.
14. Altman, D.G. et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann. Intern. Med. 134, 663-694 (2001).
15. Strom, B.L., Buyse, M., Hughes, J., Knoppers, B.M. Data sharing, year 1-access to data from industry sponsored clinical trials. N. Engl. J. Med. 371, 2052-2054 (2014).
16. European Medicines Agency. European Medicines Agency policy on publication of clinical data for medicinal products for human use. http://www.ema.europa.eu/docs/en-GB/document-library/Other/2014/10/WC500174796.pdf (2014). Accessed 20 December 2014.
17. von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int. J. Surg. 12, 1495-1499 (2014).
18. RECORD. REporting of studies Conducted using Observational Routinely collected Data (RECORD). http://www.record-statement. org/(2014).
19. Hern-an, M.A., Wilcox, A.J. Epidemiology, data sharing, the challenge of scientific replication. Epidemiology 20, 167-168 (2009).
20. Meier, C.R., Schlienger, R.G., Kraenzlin, M.E., Schlegel, B., Jick, H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283, 3205-3210 (2000).
21. Smeeth, L., Douglas, I., Hall, A.J., Hubbard, R., Evans, S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br. J. Clin. Pharmacol. 67, 99-109 (2009).
22. Suissa, S., Azoulay, L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35, 2665-2673 (2012).
23. Schneeweiss, S., Huybrechts, K.F., Gagne, J.J. Interpreting the quality of health care database studies on the comparative effectiveness of oral anticoagulants in routine care. J. Comp. Eff. Res. 3, 33-41 (2013).
24. Overhage, J.M., Ryan, P.B., Reich, C.G., Hartzema, A.G., Stang, P.E. Validation of a common data model for active safety surveillance research. J. Am. Med. Inform. Assoc. 19, 54-60 (2012).
25. Curtis, L.H., Brown, J., Platt, R. Four health data networks illustrate the potential for a shared national multipurpose big-data network. Health Aff. (Millwood) 33, 1178-1186 (2014).
26. Open Science Collaboration. Psychology. Estimating the reproducibility of psychological science. Science 349, aac4716 (2015).
27. Ebrahim, S. et al. Reanalyses of randomized clinical trial data. JAMA 312, 1024-1032 (2014).
28. Robinson, D., Schulz, E., Brown, P., Price, C. Updating the Read Codes: user interactive maintenance of a dynamic clinical vocabulary. J. Am. Med. Inform. Assoc. 4, 465-472 (1997).
29. ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol. Drug Saf. 17, 200-208 (2008).
30. US Department of Health and Human Services Food and Drug Administration. Guidance for industry and FDA staff best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data sets. http://www.rees-france. com/en/article.php3?id-article5506 (2013).
31. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP Guide on Methodological Standards in Pharmacoepidemiology. http://www.encepp.eu/standards-and-guidances/methodologicalGuide.shtml (2014).
32. Johnson, M.L., Crown, W., Martin, B.C., Dormuth, C.R., Siebert, U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part III. Value Health 12, 1062-1073 (2009).
33. Berger, M.L., Mamdani, M., Atkins, D., Johnson, M.L. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I. Value Health 12, 1044-1052 (2009).
34. Langan, S.M. et al. Setting the RECORD straight: developing a guideline for the REporting of studies Conducted using Observational Routinely collected Data. Clin. Epidemiol. 5, 29-31 (2013).
35. Gagne, J.J., Wang, S.V., Rassen, J.A., Schneeweiss, S. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiol. Drug Saf. 23, 619-627 (2014).
36. Gagne, J.J. et al. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin. Pharmacol. Ther. 92, 80-86 (2012).
37. Toh, S., Baker, M.A., Brown, J.S., Kornegay, C., Platt, R., Mini-Sentinel Investigators. Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. JAMA Intern. Med. 173, 817-819 (2013).
38. Toh, S. et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch. Intern. Med. 172, 1582-1589 (2012).
39. Solomon, D.H. et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109, 2068-2073 (2004).
40. Schneeweiss, S., Rassen, J.A., Glynn, R.J., Avorn, J., Mogun, H., Brookhart, M.A. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20, 512-522 (2009).
41. CMS 2008-2010 Data Entrepreneurs' Synthetic Public Use File (DESynPUF). https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/SynPUFs/DE-Syn-PUF.html (2014).
42. Centers for Medicare and Medicaid Services (CMS) Linkable 2008-2010 Medicare Data Entrepreneurs' Synthetic Public Use File (DESynPUF). https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/SynPUFs/Downloads/SynPUF-Codebook.pdf (2013).
43. Van Le, H., Beach, K.J., Powell, G., Pattishall, E., Ryan, P., Mera, R.M. Performance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases. Stat. Methods Med. Res.22, 97-112 (2013).